
    
      This is a randomized, open-label, multi-center, phase II clinical trial initiated by a
      investigator to observe and evaluate the efficacy of apatinib in the treatment of patients
      with failed first-line treatment after recurrence and metastasis of esophageal squamous cell
      carcinoma. Effectiveness and security.
    
  